Nrf2 dysregulation has been implicated in different aspects of CVDs [117] and multiple types of cancers (e.g., ovarian cancer [118], breast cancer [119], and glioblastoma [120]), while Nrf2 itself has been identified as a promising therapeutic target for these chronic diseases resulting from its role in providing cytoprotection against diverse stress and pathologies [121]. This evidence concerns the gene NFE2L2 and cancer.